Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors.

Ellis, P. A.; Fitzharris, Bernie; George, Paul‐Louis; Robinson, Bridget A.; Atkinson, Callum; Colls, B M

doi:10.1200/jco.1992.10.10.1609

Cited by 29 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An elevated serum cholesterol level is regarded as a major risk factor for coronary artery disease, but the biological signifi cance of the reported findings remains to be defined. Recently, Ellis et al [30] published a study which was contradictory to the aforementioned reports [9, 28,29]. Ellis et al [30] did not find significant differences with regard to fasting plasma lipid concentrations between patients treated with chemotherapy for testicular cancer and patients with germ cell tumors who did not receive chemotherapy.…”

Section: Myocardial Infarction and Coronary Artery Diseasecontrasting

confidence: 46%

Acute and Late Vascular Complications Following Chemotherapy for Germ Cell Tumors

Gerl¹,

Clemm²,

Wilmanns³

1993

Oncol Res Treat

View full text Add to dashboard Cite

Side effects of cisplatin-based chemotherapy for germ cell tumors include myelosup-pression, nephro-, neuro- and ototoxicity. These side effects as well as the pulmonary toxicity of bleomycin are dose-dependent. On the contrary, chemotherapy-associated vascular complications are unpredictable. Whereas Raynaud’s phenomenon is observed in a considerable proportion of patients, myocardial infarction, stroke, and pulmonary embolism appear to occur infrequently. The fact that some patients have been in complete remission at the time of myocardial infarction or cerebrovascular accident argues against a tumor-induced complication and is an argument in favor of a possible causative role of chemotherapy. An alteration of the clotting system and vascular smooth muscle tone as well as an endothelial cell damage are discussed to be pathogenetic mechanisms. Pulmonary embolism, on the contrary, seems to be more frequently associated with inferior vena caval obstruction by tumor masses. Presently there is a debate whether, apart from rare acute vascular events, chemotherapy for testicular cancer leads to a long-term alteration of lipid profile and thereby eventually increases cardiovascular risk.

show abstract

Section: Myocardial Infarction and Coronary Artery Diseasecontrasting

confidence: 46%

Acute and Late Vascular Complications Following Chemotherapy for Germ Cell Tumors

Gerl¹,

Clemm²,

Wilmanns³

1993

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Gietema et al [5] and Raghavan et al [27] have described hypercholesterolemia in testicular cancer pa tients who had been treated by cisplatin-based chemo therapy, whereas this has not been confirmed in another report [28], The etiology of this hypercholesterolemia remains unknown. Both overweight and hypogonadism have been discussed [5,27], In our series chemotherapy was not associated with hypercholesterolemia.…”

Section: Discussionmentioning

confidence: 83%

Clinical and Biochemical Long–Term Toxicity after Postoperative Cisplatin–Based Chemotherapy in Patients with Low-Stage Testicular Cancer

Fosså¹,

Lehne²,

Heimdal³

et al. 1995

Oncology

View full text Add to dashboard Cite

In this case-control study the long-term chemotherapy-related morbidity was assessed in testicular cancer patients (≥5 years after treatment). The case group consisted of 47 patients with nonseminomatous testicular cancer who had undergone retroperitoneal surgery and 3-4 cycles of conventional-dose cisplatin-based chemotherapy (accumulated cisplatin dose: 300-400 mg/m²), also containing vinblastine and bleomycin. The results of the clinical and biochemical investigations and the patients’ responses to a questionnaire were compared to similar observations from a control group comprising 47 patients treated with surgery only. In the case group the serum magnesium values and the levels of FVIIvWF were significantly lower (but within the normal range) than in the control group. Serum cholesterol values were distributed similarly in both groups. About 40% of the patients from the chemotherapy group still suffered from Raynaud-like phenomena and/or sensoric neurotoxicity as compared to 10% of the patients from the control group. Chemotherapy resulted in a significant elevation of serum LH within the normal range, probably associated with a slight suclinical Leydig cell dysfunction. Serum FSH levels were similar in the case and control groups, indicating an absence of long-term disturbance of spermatogenesis after chemotherapy. No increased cardiovascular morbidity was observed as a result of chemotherapy. Raynaud-like phenomena and sensoric neurotoxicity represent the principal clinical long-term side effects after 3–4 cycles of cisplatin-based chemotherapy containing vinblastine and bleomycin. Serum LH is slightly elevated after chemotherapy, whereas long-term spermatogenesis seems to be unaffected.

show abstract

“…After such cytostatic treatment, patients more often had increased serum levels of cholesterol, weight gain, hypertension and decreased renal function (Hansen et al, 1988;Ellis et al, 1992;Raghavan et al, 1992;Bokemeyer et al, 1996;Nord et al, 2003a) than the age-matched general population, or compared to MGCT patients treated by surgery only. Our data support the view of increase of diseases of the circulatory system in patients with MGCT, as our complete cohort of MGCT patients indeed displayed a marginally increased risk of dying from circulatory diseases (SMR: 1.2 (95% CI: 1.0 -1.5)).…”

Section: Discussionmentioning

confidence: 99%

“…These solid cancers develop mostly 10 years or more after radiotherapy, when patients are no longer followed up intensively by their primarily responsible oncological unit. Epidemiologically less established are observations on late adverse events related to obesity, hypercholesterolaemia and decreased kidney function and to cardiovascular events (Hansen et al, 1988;Ellis et al, 1992;Raghavan et al, 1992;Bokemeyer et al, 1996;Fosså et al, 1989;Meinardi et al, 2000;Huddart et al, 2003;Fosså et al, 2003;Nord et al, 2003a). Single-centre reports have indicated that such conditions may be associated with the modern treatment of MGCT, in particular with the use of cisplatin-based chemotherapy.…”

mentioning

confidence: 99%

Increased mortality rates in young and middle-aged patients with malignant germ cell tumours

et al. 2004

View full text Add to dashboard Cite

Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors.

Cited by 29 publications

References 18 publications

Acute and Late Vascular Complications Following Chemotherapy for Germ Cell Tumors

Acute and Late Vascular Complications Following Chemotherapy for Germ Cell Tumors

Clinical and Biochemical Long–Term Toxicity after Postoperative Cisplatin–Based Chemotherapy in Patients with Low-Stage Testicular Cancer

Increased mortality rates in young and middle-aged patients with malignant germ cell tumours

Contact Info

Product

Resources

About